Application Serial No.: 09/776,117 Filing Date: February 2, 2001

Docket: 369-123 CIP IV/RCE (BSA 00-34)

Page 2 of 12

**IN THE CLAIMS:** 

PLEASE AMEND THE CLAIMS AS FOLLOWS:

Please cancel claims 15, 16, 30, 31, 60 and 61;

Please amend claims 1, 17 and 47 as follows:

1. (Presently amended) A method for diminishing, inhibiting or eliminating

addiction-related behavior of a mammal, wherein said method comprises administering to

said mammal an effective amount of a composition consisting essentially of topiramate or a

pharmaceutically acceptable salt thereof, or an enantiomer or racemic mixture thereof, and

wherein the addiction-related behavior is associated with cocaine or nicotine addiction.

2. (Original) A method according to claim1, wherein said addiction-related

behavior is diminished, inhibited or eliminated without an aversive response to said

composition.

3. (Original) A method according to claim1, wherein said addiction-related

behavior is diminished, inhibited or eliminated without an appetitive response to said

composition.

4. (Original) A method according to claim1, wherein said addiction-related

behavior is diminished, inhibited or eliminated without an alteration in locomotor function of

said mammal.

5. (Cancelled)

6. (Original) A method according to claim 1, wherein said addiction related

Application Serial No.: 09/776,117 Filing Date: February 2, 2001

Docket: 369-123 CIP IV/RCE (BSA 00-34)

Page 3 of 12

behavior is conditioned place preference.

7-8. (Cancelled)

9. (Original) A method according to claim 1, wherein said composition

comprises topiramate administered in an amount of about 25mg to about 1g/day.

10-12. (Cancelled)

13. (Original) A method according to claim 1, wherein said composition is not

addictive to said mammal.

14. (Original) A method according to claim 1, wherein said mammal is a primate.

15-16. (Cancelled)

17. (Presently Amended) A method for diminishing, inhibiting or eliminating

cravings associated with addiction to drugs of abuse cocaine or nicotine in a mammal,

wherein said method comprises administering to said mammal an effective amount of a

composition consisting essentially of topiramate or a pharmaceutically acceptable salt

thereof, or an enantiomer or racemic mixture thereof.

18. (Original) A method according to claim 17, wherein said cravings are

diminished, inhibited or eliminated without an aversive response to said composition.

19. (Original) A method according to claim 17, wherein said cravings are

diminished, inhibited or eliminated without an appetitive response to said composition.

20. (Original) A method according to claim 17, wherein said cravings are

diminished, inhibited or eliminated without an alteration in locomotor function of said

mammal

Application Serial No.: 09/776,117 Filing Date: February 2, 2001

Docket: 369-123 CIP IV/RCE (BSA 00-34)

Page 4 of 12

21-23. (Cancelled)

24. (Original) A method according to claim 17, wherein said composition comprises topiramate administered in an amount of about 25mg to about 1g/day.

25-27. (Cancelled)

- 28. (Original) A method according to claim 17, wherein said mammal is a primate.
- 29. (Original) A method according to claim 17, wherein said composition is not addictive to said mammal.

30-46. (Cancelled)

- 47. (Presently Amended) A method for diminishing, inhibiting or eliminating dependency characteristics associated with addiction to drugs of abuse cocaine or nicotine in a mammal, wherein said method comprises administering to said mammal an effective amount of a composition consisting essentially of topiramate, or a pharmaceutically acceptable salt thereof, or an enantiomer or racemic mixture thereof.
- 48. (Original) A method according to claim 47, wherein said dependency characteristics are diminished, inhibited or eliminated without an aversive response to said composition.
- 49. (Original) A method according to claim 47, wherein said dependency characteristics are diminished, inhibited or eliminated without an appetitive response to said composition.
  - 50. (Original) A method according to claim 47, wherein said dependency

Application Serial No.: 09/776,117 Filing Date: February 2, 2001

Docket: 369-123 CIP IV/RCE (BSA 00-34)

Page 5 of 12

characteristics are diminished, inhibited or eliminated without an alteration of locomotor function in said mammal.

51-53. (Cancelled)

54. (Original) A method according to claim 47, wherein said composition comprises topiramate administered in an amount of about 25mg to about 1g/day.

55-57 (Cancelled)

- 58. (Original) A method according to claim 47, wherein said mammal is a primate.
- 59. (Original) A method according to claim 47, wherein said composition is not addictive to said mammal.

60-96. (Cancelled)